Many ethnic groups have genetic disorders that are overrepresented due to founder effects. Examples include cystic fibrosis and ␣-1-antitrypsin deficiency in European Caucasians, 1, 2 and ␣ or ␤ thalassemia in groups living in equatorial regions with endemic malaria (Medical Genetics Information Resource, http://www.genetests.org, last accessed May 4, 2009). 3 Ashkenazi Jewish (AJ) individuals are the descendents of those belonging to the Hebrew ethnic and religious group that settled in Eastern Europe in the early Middle Ages. Several autosomal recessive disorders are more common in the AJ population than in the general population (Table 1) . 4 -6 An estimated one in 4.8 AJ individuals is a carrier of one of these diseases, 8 most of which are severe and cause significant morbidity and mortality. Treatment to reduce symptoms and prolong life is available for some of these disorders, and novel treatments and therapies, including enzyme replacement therapy, have recently become available or are in development.
Most cases of these diseases in the AJ population are due to one or a few disease causing alleles. For example, three mutations account for approximately 95% of Niemann Pick (NP) chromosomes in the AJ population, while there is no common mutation associated with NP in the general population (Table 1) . Similarly, five mutations in the CFTR gene account for approximately 97% of cystic fibrosis alleles in the AJ population, whereas a set of 25 mutations accounts for only 90% in the Northern European population (and significantly less in other populations). 19, 20 Molecular testing for many of the disorders common in the AJ population has been developed and is currently in widespread use.
The American and Israeli Jewish communities have been highly supportive of population-based carrier testing and reproductive genetic counseling for carriers. Tay-Sachs disease (TSD) is the first genetic condition for which community-based carrier detection was implemented. 17, 21 In Jewish communities around the world, couples are urged to participate in screening before pregnancy and, in some cases, before marriage. Now In 2004, the American College of Obstetricians and Gynecologists recommended that individuals of AJ descent undergo prenatal and preconceptional carrier testing for TSD, Canavan disease (CD), familial dysautonomia (FD), and cystic fibrosis. Testing for mucolipidosis type IV (MLIV), NP disease type A, Fanconi anemia (FA) group C, Bloom syndrome (BS), and Gaucher disease (GD) was also suggested. 22 Although glycogen storage disorder type 1a (GSD) testing has not been recommended by American College of Obstetricians and Gynecologists, many laboratories offer this analysis because testing for two alleles, R83C and Q347C, in the G6PC gene can detect almost 100% of affected patients in the AJ population. In addition to the American College of Obstetricians and Gynecologists recommendations, the American College of Medical Genetics has recommended carrier testing for cystic fibrosis, CD, FD, TSD, and suggests that screening should be offered for FA, NP, BS, MLIV and GD. 23 Many molecular genetics laboratories currently offer testing for some or all of these disorders and often multiplex them into a single testing panel. More laboratories are expected to offer testing as the demand increases.
A variety of assay methods, including commercial analyte specific reagents and laboratory developed tests (LDTs) are in use. As with other genetic diseases, laboratories testing for AJ disorders often find it difficult to obtain reference materials (RMs) or quality control (QC) materials for test development, validation, QC, and proficiency testing/external quality assessment. This is due to the relative rarity of affected patients, paucity of archived samples in research laboratories, and lack of materials available from repositories.
To address the lack of RMs for AJ panel testing, the Centers for Disease Control and Prevention-based Genetic Testing Reference Materials Coordination Program (GeT-RM), in collaboration with members of the genetic testing community and the Coriell Cell Repositories, have created a set of 31 genomic DNA materials with confirmed mutations. These RMs were selected to include alleles representing nine disorders (BS, CD, FA, FD, GD, MLIV, NP, TSD and GSD) commonly included in clinical AJ testing panels. The alleles in these samples were confirmed by six volunteer laboratories using a variety of methods. A separate set of materials with characterized cystic fibrosis mutations has been developed and is reported separately. 24 
Materials and Methods

Cell Lines and DNA Preparation
The RM needs for AJ genetic testing were defined by consultation with clinical laboratory directors, analysis of current test panels, and assessment of available QC and RMs. Based on this analysis, 20 Epstein-Barr virus transformed lymphoblast cell lines and 11 fibroblast cell cultures were selected from the National Institute of General Medical Sciences (NIGMS) Human Genetic Cell Repository at the Coriell Cell Repositories (http://ccr.coriell.org/ Sections/Collections/NIGMS/?SsIdϭ8, last accessed April 10, 2009). These cell lines carry many of the commonly tested alleles causing the nine disorders included in this study ( Table 2) .
The cell lines were cultured using previously described methods. 25 Approximately 1 to 2 mg of DNA was prepared from each of the selected cell lines by the Coriell Cell Repositories. 26 
Laboratory Selection
Six commercial or academic clinical genetic laboratories offering AJ Panel testing volunteered to participate in this mutation confirmation study. All six of the laboratories were in the United States and were accredited by the College of American Pathologists.
Protocol
Each of the testing laboratories received blinded, 50 g aliquots of DNA from each of 27 AJ cell lines. The laboratories assayed the DNA samples one time using their current in-house method. The results were sent to the study coordinator (L.K.), who compiled the data and checked for discrepancies.
After the initial set of 27 DNA samples was tested, an additional four DNA samples (GM00059, GM01031, GM09787, and GM04863) containing mutations not identified in the initial materials became available from Coriell. Aliquots of these samples (Batch 2) were sent to four of the participating laboratories for testing. The assays used in these four laboratories represent all of the methods used with the initial 27 samples.
Assay Methods
DNA from each of the 31 cell lines was tested by three to six of the participating laboratories (depending on the disorders included in their AJ test panels). The disorders/ alleles included in each assay are shown in Table 3 . Four of the six laboratories used an assay based on commercially available reagents (xTAG) from Luminex Molecular Diagnostics (Austin, TX). The multiplexed xTAG assay detects all disorders included in this study except GSD. GSD mutations were assayed by three laboratories in this study using LDTs.
Two laboratories used PCR-based LDTs. One of these (LDT1) tested for BS, CD, FA, FD, GD, MLIV, NP, TSD, and GSD using previously described methods (Table  3) . 10 This laboratory assayed for BS, FA, and FD mutations using the Promega ReadIT SNP Genotyping System (Promega Incorporated, Madison, WI). MLIV mutations were assayed using real-time PCR on an ABI7900 (Applied Biosystems, Foster City CA), and CD, GD, NP, TSD, and GSD assays were preformed using SnapShot kits (Applied Biosystems Incorporated, Foster City, CA).
The other laboratory (LDT2 , Table 3 ) used a pooled allele-specific oligonucleotide (ASO) hybridization assay that detects mutations for 6 of the diseases (BS, CD, FA, GD, NP, and TSD). The amplified PCR products were individually immobilized on a positively charged nylon membrane and hybridized with groups of P 33 ASO probes. Mutation identification of pool-positive samples was made by individual ASO hybridization to normal and mutant alleles. This laboratory tested for mutations that cause FD, MLIV, and GSD with 5Ј nuclease Taqman assays using real-time PCR and an allelic discrimination strategy.
One laboratory (LDT 3, Table 3 ) used an LDT for GSD. In this assay, multiplex PCR using universal primer sequence-tagged primers was performed as previously described. 27 Mutations were detected using allele specific oligonucleotide hybridization. 28 Three of the laboratories used an xTAG-reagent based assay and the fourth laboratory used a PCR-based LDT to test the Batch 2 samples.
Results
We surveyed the laboratories listed on the Genetests website (http://www.genetests.org, last accessed April 10, 2009) and consulted with clinical laboratory directors to identify which disorders and mutations are commonly offered in AJ test panels. We found a wide variation in the disorders and alleles included in the AJ test panels offered by various clinical laboratories (Table 1) . Most laboratories offer tests for BS, CD, FA, FD, GD, MLIV, NP, and TSD. A few also offer tests for GSD and maple syrup urine disease.
The alleles represented in these panels also varied, but generally included the common disease-causing alleles together with some alleles present at lower frequencies in the AJ or non-Jewish populations. For example, 
*Number of labs that detected the mutation ϭ Number of labs that tested for the mutation. †
Mutations identified unexpectedly during characterization study. ‡
Allele not detected by one LDT, but detected by the same lab using the xTAG reagent. Ϫ indicates no mutation detected.
three TSD mutations, 1278insTATC, IVS12(ϩ1)GϾC, and G269S account for over 98% of mutant alleles in the AJ population. Testing for IVS9(ϩ1)GϾA and the 7.6-kb deletion is often included to increase the detection rate in the non-AJ population. 6 In addition, the R247W and R249W alleles are commonly tested to clarify abnormal enzyme test results due to the presence of these pseudodeficiency alleles. Inclusion of the A305E mutation in CD panels and delta R608 in NP mutation panels considerably increases the detection rate in the non AJ population. 6 Thirty-one cell lines were chosen from the NIGMS Cell Repository at the Coriell Cell Repositories to create an AJ RM panel. The selected lines represent alleles included in laboratory test panels for the nine disorders. Compound heterozygotes and homozygous genotypes were selected.
Six clinical genetic laboratories volunteered to characterize these materials using their current assay method. Three to six laboratories (depending on their test panels, Table 3 ) independently tested DNA prepared from the 31 cell lines for 33 different disease alleles. Twenty-five different alleles were identified in the samples (Table 2) . Alleles not detected in any sample are present at very low frequencies in affected populations (Table 1 ). All laboratories were able to detect the presence of every allele included in their assay that was present in the samples. One laboratory was unable to detect the L444P allele in DNA sample NA04394 using their LDT, but was able to detect it in sample GM08752. This laboratory, which no longer uses the LDT, was subsequently able to detect L444P in this sample with the xTAG assay. It is likely that the L444P allele in sample NA04394 represents a GBA pseudogene recombinant that interfered with this assay result. 29 There were no other discrepant results.
Discussion
This study describes the characterization of 31 genomic DNA reference materials for AJ genetic testing. These materials were selected to include heterozygous (simple and compound) and homozygous genotypes for the nine disorders (BS, CD, FA, FD, GD, MLIV, NP, TSD, and GSD) commonly included on clinical AJ testing panels. A group of six commercial and academic molecular diagnostic laboratories volunteered to test these samples using their own AJ panel assays. This arrangement allowed each of the 31 genomic DNA samples to be independently tested in three to six laboratories for 33 different alleles on a variety of test platforms.
We identified 25 different alleles in these samples (Table 2). With one exception, there were no discordant results indicating that the samples will function in a variety of assay types, including a commonly used commercial platform. All laboratories were able to confirm the expected genotype of each DNA sample. In addition, since the testing laboratories were blinded to the expected genotypes, each sample was tested for all disorders and alleles included in the laboratory's panel. This allowed us to identify an unanticipated GD mutation in three of the samples (NA02528, NA16193, and NA04863).
Although genomic DNA samples containing most of the mutations commonly included in AJ testing panels were characterized in this study and are available from Coriell, there are a number of mutations included in these panels that are not publicly available as either genomic DNA from Coriell or from other sources. These include the R696P well as the 433(Ϫ2)AϾG mutations that cause FD and CD respectively ( Table 1 ). The GeT-RM program will work with Coriell and patient communities to create cell lines and genomic DNA materials to satisfy these unmet needs.
The quality assurance of molecular genetic testing in the United States is mandated by a number of regulations and guidelines. 30 6 The lack of available QC and RMs for genetic testing has been recognized as a critical need of the genetic testing community (Centers for Disease Control and Prevention, http://www.cdc.gov/dls/pdf/genetics/dyncor.pdf, last accessed January 9, 2009). 34, 35 For the majority of genetic tests, no characterized DNA or cell lines that can be used as RMs for QC, proficiency testing/external quality assessment, genetic test development/validation, or research are publicly available. In the absence of such material, clinical laboratories and test developers use residual patient specimens, when available, or make oligonucleotides for this purpose. The lack of such materials also affects the ability of proficiency testing/external quality assessment providers to produce sufficient and varied challenges.
Cell repositories that provide genomic DNA and/or cell lines containing mutations are the only publicly available sources of DNA for RMs for most tests. 30, 34, 35 Coriell's NIGMS Human Genetic Cell Repository offers a vast array of cell lines and DNA products. However, the submissions to Coriell are voluntary and the associated information is often limited and uncorroborated. Many clinical genetic testing laboratories routinely use cell lines and DNA from the repository as positive and negative controls after characterizing them in their assay. Some companies have developed synthetic multiplex DNA controls that contain multiple mutations for a few genetic disorders, including one for the AJ Panel disorders and one company offers genomic DNA controls for pharmacogenetic assays.
To address these quality assurance needs, the GeT-RM, together with the genetic testing community and the Coriell Cell Repositories, has established a process to develop characterized genomic DNA materials for use as RMs for genetic testing. The materials being developed are intended to serve as RMs for daily use. These materials differ from standard reference materials or certified reference materials, 30, 36 which are more highly characterized and expensive and are intended for more occasional use such as assay calibration and/or assay validation.
The RMs developed by this project may be used for proficiency testing, quality control, assay development/ validation, or research applications and are publicly available from Coriell's NIGMS Human Genetic Cell Repository(http://ccr.coriell.org/Sections/Collections/NIGMS/ ?SsIdϭ8, last accessed April 10, 2009). The availability of these characterized RMs should help to ensure the quality and accuracy of AJ panel genetic testing.
Information about these and other available RM and QC materials is presented on the GeT-RM program website; http://www.cdc.gov/dls/genetics/rmmaterials/default. aspx (last accessed April 10, 2009 ).
